Curated headlines from the field's leading publications and journals — psychiatry, therapy, and behavioral health business — refreshed throughout the day.
80 stories from Psychiatric Times · Clear
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
In-person visits let Erin Crown read incongruence between what a patient says and how they present, and one encounter years ago showed her exactly why that matters.
A vague sense of 'blah' is often the last symptom to lift. Dr. Harding and Dr. Citrome examine why anhedonia and disrupted sleep persist longest, and how tracking them closely reveals early warning signs.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Gus Alva, MD, DFAPA, joins Erin Crown to discuss how regional meetings, industry exchange, and emerging treatments can help clinicians avoid burnout and better serve patients.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Medication access and cost shape ADHD outcomes as much as the prescription itself. The panel examines shortages, pricing, and the real economic toll of inadequately treated ADHD.
Patches, liquids, and a newly approved triple reuptake inhibitor are expanding the ADHD treatment toolkit. The panel discusses when to reach beyond familiar medications and how to build patient trust in doing so.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Two decades after a landmark STAR*D trial recalibrated expectations, Dr. DeBattista argues the standard of care has barely moved, and that measurement-based care remains the underused lever.
The side effect that stops the drug is usually the one nobody warned about. The panel works through what belongs in the first conversation and how often to reassess for suicidality.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
A patient's improving score does not always translate into a patient who feels better, and Erin Crown explains how anhedonia and cognitive symptoms account for the gap.
More than half of patients treated for depression don't believe full remission is achievable. The panel explores what success should mean to the patient in front of you, and why patients rarely admit they've stopped taking a medication.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Behind every extended-release stimulant is an engineering problem: how to release medication predictably over hours. The panel breaks down the microparticle and polymer technologies making that possible.
Closing the discussion, the panel offers practical guidance on patient education, ongoing clinical learning, and community-based research opportunities to help clinicians move schizophrenia care forward.
Caregivers carry an enormous, often invisible burden in schizophrenia care. The panel discusses how curiosity, communication, and community resources can support families while helping patients hold onto hope.
Sensory sensitivity, weekend flexibility, and hyperfocus all shape how adults actually take their ADHD medication. The panel explains why formulation choice can matter as much as the molecule.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
A TSH alone usually suffices, serial testing can feed anxiety, and age-specific ranges matter, an endocrinologist tells psychiatrists.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
Patients often wait years to seek therapy, arriving in crisis as gaps between prescribers and therapists slow coordinated care and complicate relationship healing.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Start low and go slow collides with therapeutic urgency more often than guidelines admit. Dr. DeBattista walks through the hepatic, renal, and cytochrome considerations that force a prescriber's hand.
The weeks spent waiting for an antidepressant to work are a window for dropout and risk. The panel debates who earns a faster-acting option up front and what monitoring that choice requires.
Explore why Hispanic patients may downplay mental health symptoms, how stigma widens the treatment gap, and how culturally responsive care builds trust.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Explore why culturally aware, collaborative psychiatric care improves outcomes for Hispanic patients—overcoming access and language barriers through trust, transparency, and shared decisions.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
AI might streamline psychiatric intake with avatar interviews and EHR-linked decision support, adding guardrails against hallucinations and enabling measurement-driven precision predictions.
Universal IPV screening across care settings helps clinicians identify hidden abuse, avoid stereotypes, and support patients with nonjudgmental resources and ongoing care.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Treatment does not end with a prescription. The panel closes by examining who owns follow-up care, and why caregivers remain the true cornerstone of managing Alzheimer's agitation over time.
When first-line therapy falls short, the decision to augment or switch is rarely straightforward. The panel examines that decision-making process alongside neurology's evolving role in managing agitation.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
IPV in men and LGBTQ+ patients often goes unseen; learn psychiatrist-led screening, safety planning, mandated reporting, and suicide-risk steps for outpatient care.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Standardized questionnaires matter, but Erin Crown leans on detailed conversation about a patient's daily routines to catch functional changes that no scale fully captures.
Can EEG microstates and brain imaging predict antipsychotic response?
Standardized rating scales define response and remission in clinical trials, but Erin Crown argues real recovery means returning fully to the life a patient had before depression began.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
Reframe psychosis as upstream glutamate-GABA circuit imbalance, with dopamine disruption downstream; muscarinic drugs reduce symptoms and boost cognition.
Non-stimulants play a growing, specific role in adult ADHD care, from tolerability limits to emotional regulation. The panel details exactly when to add one to a treatment plan.
Most patients with schizophrenia never work, drive, or build a full independent life. The panel argues that celebrating small victories and raising expectations can meaningfully change that trajectory.
Immediate-release booster doses ask patients with executive dysfunction to remember, calculate, and decide, often at the worst possible moment. The panel explains why this adherence trap undermines treatment.
Beyond dopamine, new mechanisms targeting inflammation and glutamatergic pathways are reshaping the schizophrenia pipeline. The panel discusses which emerging agents hold the most promise for patients.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Clinics must adapt to REMS-style models as esketamine teaches supervision and reimbursement lessons ahead of psilocybin’s potential FDA clearance.
Review top pipeline updates from last week.
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Motivational interviewing helps clinicians address antipsychotic ambivalence, using open-ended questions to connect LAIs or clozapine to patient goals over time.
A significant improvement on a rating scale can still leave a patient unable to function. Dr. DeBattista explains how he defines meaningful improvement and when non-response should change the plan.
Headlines and excerpts are aggregated from AACAP (JAACAP journal), American Psychiatric Association, Becker's Behavioral Health, Behavioral Health Business, Behavioral Health News, Psychiatric Times. All rights remain with the original publishers; select a headline to read the full article at the source.